Americans Will Foot The Bill For Germany's New Drug Price Controls

by Drew Johnson via PJMedia.com,

Germany just found a way to lower its own healthcare costs: make Americans pay more.

The Take

Jordan Calloway · Government Secrets & FOIA

# THE TAKE: Germany's Price Fix Is Smart Economics, Not Theft Let's cut the sanctimony: Germany negotiating drug prices down isn't "making Americans pay more"—it's rational policy that exposes our broken system. Here's the receipts: German price work because their government *actually negotiates* instead of Congress banning Medicare from haggling (thanks, PhRMA lobbying). When one market sets lower prices, pharma recoups margins elsewhere. That's basic math, not Germany screwing us. The real villain? U.S. lawmakers who've criminalized price negotiation while pretending the free market exists. It doesn't. We've got a rigged monopoly masquerading as capitalism. Germany solved their problem. We subsidize theirs *and* pay double ourselves. That's not their fault—that's regulatory capture. If we're angry about costs, aim at the Congress members still blocking Medicare negotiation rights, not Berlin for protecting their citizens. They're not taking from us. We're just overpaying.

What the Documents Show

But economic reality tells a different story. Pharmaceutical companies cannot absorb indefinite losses on research and development costs. When one wealthy nation forcibly suppresses drug , those suppressed costs don't vanish—they migrate to markets with less price control. And since most developed nations employ similar price-capping strategies, the burden concentrates almost entirely on one place: the United States. The scale of this cost-shifting is staggering.

Follow the Money

American patients generate approximately three-quarters of global pharmaceutical profits while representing only a quarter of global GDP. This disparity exists because wealthy European governments, including Germany, use their regulatory power to dictate drug prices rather than allow market mechanisms to function. French patients, German patients, and British patients pay substantially less for identical medications than Americans do. The difference isn't arbitrary—it's engineered through government policy that essentially tells pharmaceutical manufacturers: "accept our price or lose access to our market entirely." This arrangement has persisted for decades, largely unremarked upon by mainstream media outlets that frame American healthcare costs as a purely domestic problem. The conventional narrative blames American insurers, hospital administrators, or pharmaceutical executives for high drug prices without acknowledging the international dimension. What receives less coverage is how foreign price controls externalize costs northward, making the United States a de facto funding mechanism for global pharmaceutical innovation.

What Else We Know

European patients benefit from treatments developed largely at American expense. The mechanism works like this: a company invests billions developing a drug. Germany announces it will pay only a fraction of that drug's research costs. The company cannot sustain operations by accepting such terms across all markets. Instead, it compensates through American pricing, where regulatory frameworks permit higher prices. American insurance companies and uninsured patients then absorb costs that Germans refused to pay.

Primary Sources

• Source: ZeroHedge
• Category: Government Secrets
• Cross-reference independently — don't take our word for it.

Disclosure: NewsAnarchist aggregates from public records, API feeds (Federal Register, CourtListener, MuckRock, Hacker News), and independent media. AI-assisted synthesis. Always verify primary sources linked above.